Last reviewed · How we verify

NCT05736354: MMABIC

Molecular Mechanisms Associated With Breast Implant Complications

Recruiting now Last updated 10 April 2025
What this trial tests

trial in Breast Implant; Complications in 1,000 participants. Currently enrolling.

Timeline
3 January 2021
Primary endpoint
30 June 2028
30 June 2028

Quick facts

Lead sponsorIndiana University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date3 January 2021
Primary completion30 June 2028
Estimated completion30 June 2028
Sites3 locations across United States

Conditions studied

Sponsor

Indiana University

Who can join

18 and older, female only, with Breast Implant; Complications or Infection or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bacterial biofilms cause implant failures, chronic inflammation, and immune polarization. The study investigates the possible role of bacterial biofilm as a factor in the etiology of Breast Implant Illness. Three patient cohorts will be studied (A) Subjects with breast implant with BII manifestations (B) Subjects with breast implants without BII manifestations (C) Subjects without breast implants who underwent breast surgery procedure. Blood, surgically discarded tissue, implants, and associated capsules will be collected through this protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Implant; Complications

Currently open trials in the same condition.

Other Indiana University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05736354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing